Literature DB >> 12805467

Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.

Nicole R Kilgore1, Karl Salzwedel, Mary Reddick, Graham P Allaway, Carl T Wild.   

Abstract

While it has been established that peptides modeling the C-helical region of human immunodeficiency virus type 1 gp41 are potent in vivo inhibitors of virus replication, their mechanism of action has yet to be determined. It has been proposed, but never directly demonstrated, that these peptides block virus entry by interacting with gp41 to disrupt the formation or function of a six-helix bundle structure. Using a six-helix bundle-specific monoclonal antibody with isolate-restricted Env reactivity, we provide the first direct evidence that, in receptor-activated viral Env, C-peptide entry inhibitors bind to the gp41 N-helical coiled-coil to form a peptide/protein hybrid structure and, in doing so, disrupt native six-helix bundle formation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12805467      PMCID: PMC164814          DOI: 10.1128/jvi.77.13.7669-7672.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage.

Authors:  Y Kliger; S A Gallo; S G Peisajovich; I Munoz-Barroso; S Avkin; R Blumenthal; Y Shai
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

2.  Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/leucine zipper-like sequence.

Authors:  P Poumbourios; K A Wilson; R J Center; W El Ahmar; B E Kemp
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Atomic structure of the ectodomain from HIV-1 gp41.

Authors:  W Weissenhorn; A Dessen; S C Harrison; J J Skehel; D C Wiley
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

4.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

5.  Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure.

Authors:  P Poumbourios; W el Ahmar; D A McPhee; B E Kemp
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

6.  Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains.

Authors:  E J Park; G V Quinnan
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein.

Authors:  P L Earl; C C Broder; R W Doms; B Moss
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

8.  Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoprotein.

Authors:  E de Rosny; R Vassell; P T Wingfield; C T Wild; C D Weiss
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity.

Authors:  J W Dubay; S J Roberts; B Brody; E Hunter
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

10.  Two interaction modes of the gp41-derived peptides with gp41 and their correlation with antimembrane fusion activity.

Authors:  J R Ryu; B S Jin; M J Suh; Y S Yoo; S H Yoon; E R Woo; Y G Yu
Journal:  Biochem Biophys Res Commun       Date:  1999-11-30       Impact factor: 3.575

View more
  38 in total

1.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.

Authors:  Min Zhuang; Wei Wang; Christopher J De Feo; Russell Vassell; Carol D Weiss
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

3.  Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HR2) of gp41.

Authors:  Wei Wang; Christopher J De Feo; Min Zhuang; Russell Vassell; Carol D Weiss
Journal:  J Virol       Date:  2011-10-12       Impact factor: 5.103

4.  Role for the terminal clasp of HIV-1 gp41 glycoprotein in the initiation of membrane fusion.

Authors:  Chan-Sien Lay; Louise E Ludlow; David Stapleton; Anna K Bellamy-McIntyre; Paul A Ramsland; Heidi E Drummer; Pantelis Poumbourios
Journal:  J Biol Chem       Date:  2011-10-05       Impact factor: 5.157

5.  An antibody directed against the fusion peptide of Junin virus envelope glycoprotein GPC inhibits pH-induced membrane fusion.

Authors:  Joanne York; Jody D Berry; Ute Ströher; Qunnu Li; Heinz Feldmann; Min Lu; Meg Trahey; Jack H Nunberg
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

6.  Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain.

Authors:  Yael Wexler-Cohen; Avraham Ashkenazi; Mathias Viard; Robert Blumenthal; Yechiel Shai
Journal:  FASEB J       Date:  2010-07-06       Impact factor: 5.191

7.  Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.

Authors:  Antony S Dimitrov; John M Louis; Carole A Bewley; G Marius Clore; Robert Blumenthal
Journal:  Biochemistry       Date:  2005-09-20       Impact factor: 3.162

8.  A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41.

Authors:  Miriam Gochin; Ryan Savage; Spencer Hinckley; Lifeng Cai
Journal:  Biol Chem       Date:  2006-04       Impact factor: 3.915

9.  A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.

Authors:  Lifeng Cai; Miriam Gochin
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

10.  Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.

Authors:  Kelly Champagne; Akira Shishido; Michael J Root
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.